 SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 GLOBE NEWSWIRE -- Harpoon Therapeutics, Inc. NASDAQ: HARP, a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a clinical update for its three most advanced TriTAC programs. The discussion will be focused on HPN424 for the treatment of metastatic castration resistant prostate cancer, HPN536 initially in development for ovarian and pancreatic cancer and mesothelioma, and HPN217 for relapsedrefractory multiple myeloma. 